Mersana Therapeutics (MRSN) Q1 2025 earnings summary

Executive summary

• Announced a strategic restructuring in May 2025, reducing workforce by 55%, eliminating internal pipeline development, and narrowing clinical focus to breast cancer, specifically TNBC, to extend cash runway into mid-2026.

• Presented updated Phase 1 clinical data for Emi-Le (XMT-1660) at ESMO Breast Cancer 2025, showing improved ORR and encouraging PFS/OS in TNBC patients with high B7-H4 expression.

• Enrollment in expansion cohorts for Emi-Le is progressing rapidly, with new dosing regimens implemented and initial expansion data expected in H2 2025.

• Continued progress in XMT-2056 Phase 1 trial, with initial STING activation data anticipated in 2025; GSK holds global license option.

• Ongoing collaborations with GSK, Johnson & Johnson, and Merck KGaA are primary revenue sources, though at reduced levels.

Financial highlights

• Ended Q1 2025 with $102.3 million in cash and cash equivalents, supporting operations into mid-2026.

• Net cash used in operating activities was $29.3 million for Q1 2025.

• Collaboration revenue was $2.8 million, down from $9.2 million year-over-year due to reduced revenue from Johnson & Johnson and Merck KGaA agreements.

• Research and development expenses were $18.3 million, slightly down from $18.7 million year-over-year; general and administrative expenses declined to $8.9 million from $11.6 million.

• Net loss for Q1 2025 was $24.1 million ($0.19 per share), compared to $19.3 million ($0.16 per share) in Q1 2024.

Outlook and guidance

• Cash runway expected to last into mid-2026, not including potential future milestone or collaboration payments.

• Initial clinical data from Emi-Le expansion cohorts anticipated in the second half of 2025; XMT-2056 pharmacodynamic data also expected in 2025.

• No plans to expand beyond breast cancer in 2025 due to restructuring; ovarian and endometrial data will be presented but not expanded.

• Substantial doubt remains about ability to continue as a going concern without additional capital.